1. 432 Correlative analyses of serum biomarkers and clinical outcomes in the phase 2 study of lenvatinib, everolimus, and the combination, in patients with metastatic renal cell carcinoma following 1 VEGF-targeted therapy. (September 2015) Authors: Glen, H.; Hsieh, J.; Michaelson, M.D.; Kim, H.J.; Sachdev, P.; Kadowaki, T.; Funahashi, Y.; Larkin, J.; Motzer, R. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S89 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 854PDPazopanib (p) or sorafenib (s) + radium-223 (rad) in metastatic renal cell carcinoma (mrcc) with bone metastases (bm). (18th September 2017) Authors: Bossé, D.; McKay, R.R.; Gray, K.P.; Michaelson, M.D.; Sleeper, C.; Walsh, M.; Krajewski, K.M.; Jacene, H.; Bellmunt, J.; Pomerantz, M.M.; Harshman, L.C.; Choueiri, T.K. Journal: Annals of oncology Issue: Volume 28(2017)Supplement 5 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗